Newer antihypertensive therapy reduces cardiovascular eventsBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7516.533-a (Published 08 September 2005) Cite this as: BMJ 2005;331:533
- Susan Mayor
Antihypertensive therapy based on the calcium channel blocker amlodipine, with the angiotensin converting enzyme inhibitor perindopril added as required, reduced cardiovascular events compared with treatment based on the β blocker atenolol, according to the final results from the Anglo-Scandinavian cardiac out-comes trial-blood pressure lowering arm (ASCOT-BPLA) trial published online this week in the Lancet (http://www.lancet.com/, doi:10.1016/S0140-6736(05)67186-3).
The trial randomised 19 257 hypertensive patients aged 40-79 years with at least three other cardiovascular risk factors to one of two antihypertensive regimens—amlodipine (5-10 mg) with or without perindopril (4-8 mg), or atenolol (50-100 mg) with or without the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial